Trial · NCT07896928
Study of Allogeneic Stem Cell Transplant in Myelodysplastic Syndrome Following Conditioning With Fludarabine and Total Body Irradiation 800 cGy
NCT07896928, Phase 2, Not yet recruiting, Ronald Paquette
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Allogeneic Stem Cell Transplant in Myelodysplastic Syndrome Following Conditioning With Fludarabine and Total Body Irradiation 800 cGy. Trials, record NCT07896928. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07896928
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Allogeneic Stem Cell Transplant in Myelodysplastic Syndrome Following Conditioning With Fludarabine and Total Body Irradiation 800 cGy
- NCT number
- NCT07896928
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 20 participants, estimated
- Lead sponsor
- Ronald Paquette
- Conditions
- MDS, Myelodysplastic Syndrome MDS, Myelodysplastic Syndrome (MDS), Myelodysplastic Syndrome
- Interventions
- Allogeneic Stem Cell Transplant
- First posted
- 2026-10-27
- Last updated
- 2026-10-28
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Survival (OS) | 1 year following transplantation | Evaluate the 1-year OS of two groups of MDS patients following allogeneic stem cell transplantation: transfusion-dependent lower-risk patients and patients with TP53 mutations/deletions with VAF \<50%. |
| Secondary | Time to neutrophil and platelet engraftment | 30 days after PTCy Administration | Measure the time to neutrophil and platelet engraftment |
| Secondary | Rate of Acute Graft-versus-host disease (GVHD) | 100 days after PTCy Administration | Evaluate the rate of acute GVHD by 100 days |
| Secondary | Severity of Acute Graft-versus-host disease (GVHD) | 100 days after PTCy Administration | Evaluate the severity of acute GVHD by 100 days |
| Secondary | Rate of Acute Graft-versus-host disease (GVHD) | 1 year after PTCy Administration | Evaluate the rate of acute GVHD by 1 year |
| Secondary | Severity of Acute Graft-versus-host disease (GVHD) | 1 year after PTCy Administration | Evaluate the severity of acute GVHD by 1 year |
| Secondary | Non-relapse mortality | 30 days after PTCy Administration, 1 year after PTCy Administration | Assess rate of non-relapse mortality at 30 days and 1 year |
| Secondary | Relapse Rate | 1 year after PTCy Administration | Determine the relapse rate at 1 year |
| Secondary | GVHD-free relapse-free survival (GRFS) | 1 year after PTCy Administration | Calculate the rate of GVHD-free relapse-free survival (GRFS) at 1 year |
| Secondary | Transfusion-independence | 1 year after PTCy Administration | Determine the frequency of transfusion-independence at 1 year |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07896928
GET https://conductscience.org/api/trials/v1/NCT07896928/registered